Singh Sandeep, Chellappan Srikumar
National Institute of Biomedical Genomics (NIBMG), TB Hospital Building, 2nd floor, Kalyani, West Bengal, India.
Department of Tumor Biology, H. Lee Moffitt cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, United States.
Mol Aspects Med. 2014 Oct;39:50-60. doi: 10.1016/j.mam.2013.08.003. Epub 2013 Sep 7.
Lung cancers are highly heterogeneous and resistant to available therapeutic agents, with a five year survival rate of less than 15%. Despite significant advances in our knowledge of the genetic alterations and aberrations in signaling pathways, it has been difficult to determine the basis of lung cancer heterogeneity and drug resistance. Cancer stem cell model has attracted a significant amount of attention in recent years as a viable explanation for the heterogeneity, drug resistance, dormancy and recurrence and metastasis of various tumors. At the same time, cancer stem cells have been relatively less characterized in lung cancers. This review summarizes the current understanding of lung cancer stem cells, including their molecular features and signaling pathways that drive their stemness. This review also discusses the potential startegies to inhibit the signaling pathways driving stemness, in an effort to eradicate these cells to combat lung cancer.
肺癌具有高度异质性，且对现有治疗药物具有抗性，其五年生存率低于15%。尽管我们对肺癌信号通路中的基因改变和畸变的认识有了显著进展，但仍难以确定肺癌异质性和耐药性的基础。近年来，癌症干细胞模型作为各种肿瘤的异质性、耐药性、休眠以及复发和转移的一种可行解释，已引起了广泛关注。与此同时，肺癌中癌症干细胞的特征相对较少被描述。本综述总结了目前对肺癌干细胞的认识，包括它们的分子特征以及驱动其干性的信号通路。本综述还讨论了抑制驱动干性的信号通路的潜在策略，以期根除这些细胞来对抗肺癌。
